Found: 9
Select item for more details and to access through your institution.
2486. Clinical Outcomes of Patients Treated with Dolutegravir Functional Monotherapy or Dolutegravir plus an Active Non-cytosine Nucleoside Analog: A Retrospective Observational Cohort Study of Treatment-Experienced Patients.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S861, doi. 10.1093/ofid/ofz360.2164
- By:
- Publication type:
- Article
2482. Clinical Outcomes of Once-Daily Darunavir in Treatment-Experienced Patients with Darunavir Resistance Associated Mutations Through 48 Weeks of Treatment.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S859, doi. 10.1093/ofid/ofz360.2160
- By:
- Publication type:
- Article
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting.
- Published in:
- Antiviral Therapy, 2023, v. 28, n. 2, p. 1, doi. 10.1177/13596535231163703
- By:
- Publication type:
- Article
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV.
- Published in:
- AIDS Research & Therapy, 2021, v. 18, n. 1, p. 1, doi. 10.1186/s12981-021-00352-0
- By:
- Publication type:
- Article
Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.
- Published in:
- 2015
- By:
- Publication type:
- journal article
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
- Published in:
- PLoS ONE, 2020, v. 15, n. 1, p. 1, doi. 10.1371/journal.pone.0224875
- By:
- Publication type:
- Article
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
- Published in:
- Liver International, 2016, v. 36, n. 2, p. 189, doi. 10.1111/liv.12964
- By:
- Publication type:
- Article
SWITCH TO DOR/ISL (100/0.75MG) QD: WEEK 48 RESULTS FROM AN OPEN-LABEL PHASE 3 TRIAL.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 80
- By:
- Publication type:
- Article